An  ||| S:0 E:3 ||| DT
evaluation  ||| S:3 E:14 ||| NN
of  ||| S:14 E:17 ||| IN
neutralizing  ||| S:17 E:30 ||| JJ
antibody  ||| S:30 E:39 ||| NN
induction  ||| S:39 E:49 ||| NN
during  ||| S:49 E:56 ||| IN
treatment  ||| S:56 E:66 ||| NN
of  ||| S:66 E:69 ||| IN
glabellar  ||| S:69 E:79 ||| JJ
lines  ||| S:79 E:85 ||| NNS
with  ||| S:85 E:90 ||| IN
a  ||| S:90 E:92 ||| DT
new  ||| S:92 E:96 ||| JJ
US  ||| S:96 E:99 ||| NNP
formulation  ||| S:99 E:111 ||| NN
of  ||| S:111 E:114 ||| IN
botulinum  ||| S:114 E:124 ||| JJ
neurotoxin  ||| S:124 E:135 ||| JJ
type  ||| S:135 E:140 ||| NN
A  ||| S:140 E:142 ||| DT
The  ||| S:142 E:146 ||| DT
induction  ||| S:146 E:156 ||| NN
of  ||| S:156 E:159 ||| IN
neutralizing  ||| S:159 E:172 ||| JJ
antibodies  ||| S:172 E:183 ||| NNS
during  ||| S:183 E:190 ||| IN
the  ||| S:190 E:194 ||| DT
aesthetic  ||| S:194 E:204 ||| JJ
application  ||| S:204 E:216 ||| NN
of  ||| S:216 E:219 ||| IN
botulinum  ||| S:219 E:229 ||| JJ
neurotoxin  ||| S:229 E:240 ||| JJ
type  ||| S:240 E:245 ||| NN
A  ||| S:245 E:247 ||| DT
is  ||| S:247 E:250 ||| VBZ
rare ||| S:250 E:254 ||| JJ
,  ||| S:254 E:256 ||| ,
but  ||| S:256 E:260 ||| CC
of  ||| S:260 E:263 ||| IN
potential  ||| S:263 E:273 ||| JJ
clinical  ||| S:273 E:282 ||| JJ
concern ||| S:282 E:289 ||| NN
.  ||| S:289 E:291 ||| .
Phase  ||| S:291 E:297 ||| NNP
III  ||| S:297 E:301 ||| NNP
studies  ||| S:301 E:309 ||| NNS
of  ||| S:309 E:312 ||| IN
a  ||| S:312 E:314 ||| DT
new  ||| S:314 E:318 ||| JJ
US  ||| S:318 E:321 ||| NNP
formulation  ||| S:321 E:333 ||| NN
of  ||| S:333 E:336 ||| IN
botulinum  ||| S:336 E:346 ||| JJ
neurotoxin  ||| S:346 E:357 ||| JJ
type  ||| S:357 E:362 ||| NN
A ||| S:362 E:363 ||| NN
,  ||| S:363 E:365 ||| ,
Dysport  ||| S:365 E:373 ||| NNP
( ||| S:373 E:374 ||| -LRB-
BoNTA-ABO  ||| S:374 E:384 ||| NNP
[ ||| S:384 E:385 ||| -LRB-
abobotulinumtoxinA ||| S:385 E:403 ||| NNP
] ||| S:403 E:404 ||| -RRB-
;  ||| S:404 E:406 ||| :
Medicis  ||| S:406 E:414 ||| NNP
Aesthetics ||| S:414 E:424 ||| NNP
,  ||| S:424 E:426 ||| ,
Scottsdale ||| S:426 E:436 ||| NNP
,  ||| S:436 E:438 ||| ,
AZ ||| S:438 E:440 ||| NNP
) ||| S:440 E:441 ||| -RRB-
,  ||| S:441 E:443 ||| ,
have  ||| S:443 E:448 ||| VBP
not  ||| S:448 E:452 ||| RB
identified  ||| S:452 E:463 ||| VBN
any  ||| S:463 E:467 ||| DT
cases  ||| S:467 E:473 ||| NNS
of  ||| S:473 E:476 ||| IN
neutralizing  ||| S:476 E:489 ||| JJ
antibody  ||| S:489 E:498 ||| NN
formation  ||| S:498 E:508 ||| NN
during  ||| S:508 E:515 ||| IN
the  ||| S:515 E:519 ||| DT
treatment  ||| S:519 E:529 ||| NN
of  ||| S:529 E:532 ||| IN
glabellar  ||| S:532 E:542 ||| JJ
lines  ||| S:542 E:548 ||| NNS
in  ||| S:548 E:551 ||| IN
patients  ||| S:551 E:560 ||| NNS
who  ||| S:560 E:564 ||| WP
received  ||| S:564 E:573 ||| VBD
up  ||| S:573 E:576 ||| RP
to  ||| S:576 E:579 ||| TO
nine  ||| S:579 E:584 ||| CD
treatments ||| S:584 E:594 ||| NNS
.  ||| S:594 E:596 ||| .
To  ||| S:596 E:599 ||| TO
provide  ||| S:599 E:607 ||| VB
an  ||| S:607 E:610 ||| DT
in-depth  ||| S:610 E:619 ||| JJ
analysis  ||| S:619 E:628 ||| NN
of  ||| S:628 E:631 ||| IN
the  ||| S:631 E:635 ||| DT
potential  ||| S:635 E:645 ||| NN
for  ||| S:645 E:649 ||| IN
induction  ||| S:649 E:659 ||| NN
of  ||| S:659 E:662 ||| IN
neutralizing  ||| S:662 E:675 ||| JJ
antibodies  ||| S:675 E:686 ||| NNS
in  ||| S:686 E:689 ||| IN
the  ||| S:689 E:693 ||| DT
study  ||| S:693 E:699 ||| NN
population  ||| S:699 E:710 ||| NN
enrolled  ||| S:710 E:719 ||| NN
in  ||| S:719 E:722 ||| IN
phase  ||| S:722 E:728 ||| NN
III  ||| S:728 E:732 ||| NNP
trials  ||| S:732 E:739 ||| NNS
of  ||| S:739 E:742 ||| IN
BoNTA-ABO  ||| S:742 E:752 ||| JJ
in  ||| S:752 E:755 ||| IN
the  ||| S:755 E:759 ||| DT
treatment  ||| S:759 E:769 ||| NN
of  ||| S:769 E:772 ||| IN
glabellar  ||| S:772 E:782 ||| JJ
lines ||| S:782 E:787 ||| NNS
.  ||| S:787 E:789 ||| .
First  ||| S:789 E:795 ||| NNP
and  ||| S:795 E:799 ||| CC
last  ||| S:799 E:804 ||| JJ
available  ||| S:804 E:814 ||| JJ
serum  ||| S:814 E:820 ||| JJ
samples  ||| S:820 E:828 ||| NNS
from  ||| S:828 E:833 ||| IN
patients  ||| S:833 E:842 ||| NNS
in  ||| S:842 E:845 ||| IN
the  ||| S:845 E:849 ||| DT
BoNTA-ABO  ||| S:849 E:859 ||| JJ
Glabellar  ||| S:859 E:869 ||| NNP
Lines  ||| S:869 E:875 ||| NNPS
Development  ||| S:875 E:887 ||| NNP
Program  ||| S:887 E:895 ||| NNP
were  ||| S:895 E:900 ||| VBD
screened  ||| S:900 E:909 ||| VBN
for  ||| S:909 E:913 ||| IN
BoNTA-ABO  ||| S:913 E:923 ||| JJ
antibodies  ||| S:923 E:934 ||| NNS
with  ||| S:934 E:939 ||| IN
a  ||| S:939 E:941 ||| DT
radioimmunoprecipitation  ||| S:941 E:966 ||| JJ
assay  ||| S:966 E:972 ||| NNS
( ||| S:972 E:973 ||| -LRB-
RIPA ||| S:973 E:977 ||| NNP
) ||| S:977 E:978 ||| -RRB-
,  ||| S:978 E:980 ||| ,
followed  ||| S:980 E:989 ||| VBN
by  ||| S:989 E:992 ||| IN
a  ||| S:992 E:994 ||| DT
confirmatory  ||| S:994 E:1007 ||| JJ
competitive  ||| S:1007 E:1019 ||| JJ
assay  ||| S:1019 E:1025 ||| NNS
( ||| S:1025 E:1026 ||| -LRB-
RIPA-C ||| S:1026 E:1032 ||| NNP
) ||| S:1032 E:1033 ||| -RRB-
.  ||| S:1033 E:1035 ||| .
Confirmed  ||| S:1035 E:1045 ||| VBN
RIPA-C-positive  ||| S:1045 E:1061 ||| JJ
samples  ||| S:1061 E:1069 ||| NNS
were  ||| S:1069 E:1074 ||| VBD
further  ||| S:1074 E:1082 ||| RB
evaluated  ||| S:1082 E:1092 ||| VBN
for  ||| S:1092 E:1096 ||| IN
the  ||| S:1096 E:1100 ||| DT
presence  ||| S:1100 E:1109 ||| NN
of  ||| S:1109 E:1112 ||| IN
neutralizing  ||| S:1112 E:1125 ||| JJ
antibodies  ||| S:1125 E:1136 ||| NNS
using  ||| S:1136 E:1142 ||| VBG
a  ||| S:1142 E:1144 ||| DT
mouse  ||| S:1144 E:1150 ||| NN
protection  ||| S:1150 E:1161 ||| NN
assay  ||| S:1161 E:1167 ||| NNS
( ||| S:1167 E:1168 ||| -LRB-
MPA ||| S:1168 E:1171 ||| NNP
) ||| S:1171 E:1172 ||| -RRB-
,  ||| S:1172 E:1174 ||| ,
a  ||| S:1174 E:1176 ||| DT
highly  ||| S:1176 E:1183 ||| RB
specific  ||| S:1183 E:1192 ||| JJ
bioassay  ||| S:1192 E:1201 ||| NN
for  ||| S:1201 E:1205 ||| IN
neutralizing  ||| S:1205 E:1218 ||| JJ
antibodies ||| S:1218 E:1228 ||| NNS
.  ||| S:1228 E:1230 ||| .
We  ||| S:1230 E:1233 ||| PRP
conducted  ||| S:1233 E:1243 ||| VBD
safety  ||| S:1243 E:1250 ||| NN
and  ||| S:1250 E:1254 ||| CC
efficacy  ||| S:1254 E:1263 ||| JJ
evaluations ||| S:1263 E:1274 ||| NNS
,  ||| S:1274 E:1276 ||| ,
including  ||| S:1276 E:1286 ||| VBG
day  ||| S:1286 E:1290 ||| NN
30  ||| S:1290 E:1293 ||| CD
responder  ||| S:1293 E:1303 ||| JJ
rate  ||| S:1303 E:1308 ||| NN
( ||| S:1308 E:1309 ||| -LRB-
a  ||| S:1309 E:1311 ||| DT
rating  ||| S:1311 E:1318 ||| NN
of  ||| S:1318 E:1321 ||| IN
no  ||| S:1321 E:1324 ||| DT
or  ||| S:1324 E:1327 ||| CC
mild  ||| S:1327 E:1332 ||| JJ
glabellar  ||| S:1332 E:1342 ||| JJ
lines ||| S:1342 E:1347 ||| NNS
)  ||| S:1347 E:1349 ||| -RRB-
and  ||| S:1349 E:1353 ||| CC
duration  ||| S:1353 E:1362 ||| NN
of  ||| S:1362 E:1365 ||| IN
response  ||| S:1365 E:1374 ||| NN
in  ||| S:1374 E:1377 ||| IN
the  ||| S:1377 E:1381 ||| DT
last  ||| S:1381 E:1386 ||| JJ
treatment  ||| S:1386 E:1396 ||| NN
cycle ||| S:1396 E:1401 ||| NN
.  ||| S:1401 E:1403 ||| .
Of  ||| S:1403 E:1406 ||| IN
1554  ||| S:1406 E:1411 ||| CD
patients  ||| S:1411 E:1420 ||| NNS
who  ||| S:1420 E:1424 ||| WP
received  ||| S:1424 E:1433 ||| VBD
at  ||| S:1433 E:1436 ||| IN
least  ||| S:1436 E:1442 ||| JJS
one  ||| S:1442 E:1446 ||| CD
BoNTA-ABO  ||| S:1446 E:1456 ||| JJ
treatment  ||| S:1456 E:1466 ||| NN
( ||| S:1466 E:1467 ||| -LRB-
10  ||| S:1467 E:1470 ||| CD
units  ||| S:1470 E:1476 ||| NNS
at  ||| S:1476 E:1479 ||| IN
five  ||| S:1479 E:1484 ||| CD
injection  ||| S:1484 E:1494 ||| NN
points ||| S:1494 E:1500 ||| NNS
,  ||| S:1500 E:1502 ||| ,
for  ||| S:1502 E:1506 ||| IN
a  ||| S:1506 E:1508 ||| DT
total  ||| S:1508 E:1514 ||| JJ
dose  ||| S:1514 E:1519 ||| NN
of  ||| S:1519 E:1522 ||| IN
50  ||| S:1522 E:1525 ||| CD
units ||| S:1525 E:1530 ||| NNS
/ ||| S:1530 E:1531 ||| JJ
treatment ||| S:1531 E:1540 ||| NN
;  ||| S:1540 E:1542 ||| :
range  ||| S:1542 E:1548 ||| NN
one  ||| S:1548 E:1552 ||| CD
to  ||| S:1552 E:1555 ||| TO
nine  ||| S:1555 E:1560 ||| CD
treatments ||| S:1560 E:1570 ||| NNS
) ||| S:1570 E:1571 ||| -RRB-
,  ||| S:1571 E:1573 ||| ,
five  ||| S:1573 E:1578 ||| CD
( ||| S:1578 E:1579 ||| -LRB-
0.32 ||| S:1579 E:1583 ||| CD
% ||| S:1583 E:1584 ||| NN
)  ||| S:1584 E:1586 ||| -RRB-
were  ||| S:1586 E:1591 ||| VBD
antibody  ||| S:1591 E:1600 ||| JJ
positive  ||| S:1600 E:1609 ||| JJ
on  ||| S:1609 E:1612 ||| IN
the  ||| S:1612 E:1616 ||| DT
RIPA-C  ||| S:1616 E:1623 ||| JJ
assay-two  ||| S:1623 E:1633 ||| NN
at  ||| S:1633 E:1636 ||| IN
baseline  ||| S:1636 E:1645 ||| NN
and  ||| S:1645 E:1649 ||| CC
three  ||| S:1649 E:1655 ||| CD
at  ||| S:1655 E:1658 ||| IN
the  ||| S:1658 E:1662 ||| DT
last  ||| S:1662 E:1667 ||| JJ
treatment  ||| S:1667 E:1677 ||| NN
cycle ||| S:1677 E:1682 ||| NN
.  ||| S:1682 E:1684 ||| .
None  ||| S:1684 E:1689 ||| NN
of  ||| S:1689 E:1692 ||| IN
the  ||| S:1692 E:1696 ||| DT
RIPA-C-positive  ||| S:1696 E:1712 ||| JJ
samples  ||| S:1712 E:1720 ||| NNS
tested  ||| S:1720 E:1727 ||| VBD
positive  ||| S:1727 E:1736 ||| JJ
for  ||| S:1736 E:1740 ||| IN
neutralizing  ||| S:1740 E:1753 ||| JJ
antibodies  ||| S:1753 E:1764 ||| NNS
upon  ||| S:1764 E:1769 ||| IN
further  ||| S:1769 E:1777 ||| JJ
evaluation  ||| S:1777 E:1788 ||| NN
using  ||| S:1788 E:1794 ||| VBG
the  ||| S:1794 E:1798 ||| DT
highly  ||| S:1798 E:1805 ||| RB
specific  ||| S:1805 E:1814 ||| JJ
MPA ||| S:1814 E:1817 ||| NNP
.  ||| S:1817 E:1819 ||| .
Of  ||| S:1819 E:1822 ||| IN
note ||| S:1822 E:1826 ||| NN
,  ||| S:1826 E:1828 ||| ,
the  ||| S:1828 E:1832 ||| DT
RIPA-C-positive  ||| S:1832 E:1848 ||| JJ
group  ||| S:1848 E:1854 ||| NN
had  ||| S:1854 E:1858 ||| VBD
a  ||| S:1858 E:1860 ||| DT
responder  ||| S:1860 E:1870 ||| JJ
rate  ||| S:1870 E:1875 ||| NN
of  ||| S:1875 E:1878 ||| IN
100 ||| S:1878 E:1881 ||| CD
%  ||| S:1881 E:1883 ||| NN
and  ||| S:1883 E:1887 ||| CC
a  ||| S:1887 E:1889 ||| DT
mean  ||| S:1889 E:1894 ||| JJ
response  ||| S:1894 E:1903 ||| NN
of  ||| S:1903 E:1906 ||| IN
103.3  ||| S:1906 E:1912 ||| CD
days ||| S:1912 E:1916 ||| NNS
,  ||| S:1916 E:1918 ||| ,
while  ||| S:1918 E:1924 ||| IN
the  ||| S:1924 E:1928 ||| DT
RIPA-C-negative  ||| S:1928 E:1944 ||| JJ
group  ||| S:1944 E:1950 ||| NN
had  ||| S:1950 E:1954 ||| VBD
a  ||| S:1954 E:1956 ||| DT
responder  ||| S:1956 E:1966 ||| JJ
rate  ||| S:1966 E:1971 ||| NN
of  ||| S:1971 E:1974 ||| IN
90 ||| S:1974 E:1976 ||| CD
%  ||| S:1976 E:1978 ||| NN
and  ||| S:1978 E:1982 ||| CC
a  ||| S:1982 E:1984 ||| DT
mean  ||| S:1984 E:1989 ||| JJ
response  ||| S:1989 E:1998 ||| NN
of  ||| S:1998 E:2001 ||| IN
89.4  ||| S:2001 E:2006 ||| CD
days ||| S:2006 E:2010 ||| NNS
.  ||| S:2010 E:2012 ||| .
The  ||| S:2012 E:2016 ||| DT
safety  ||| S:2016 E:2023 ||| NN
of  ||| S:2023 E:2026 ||| IN
BoNTA-ABO  ||| S:2026 E:2036 ||| NNP
did  ||| S:2036 E:2040 ||| VBD
not  ||| S:2040 E:2044 ||| RB
appear  ||| S:2044 E:2051 ||| VB
to  ||| S:2051 E:2054 ||| TO
be  ||| S:2054 E:2057 ||| VB
altered  ||| S:2057 E:2065 ||| VBN
in  ||| S:2065 E:2068 ||| IN
the  ||| S:2068 E:2072 ||| DT
RIPA-C-positive  ||| S:2072 E:2088 ||| JJ
group ||| S:2088 E:2093 ||| NN
.  ||| S:2093 E:2095 ||| .
At  ||| S:2095 E:2098 ||| IN
the  ||| S:2098 E:2102 ||| DT
dose  ||| S:2102 E:2107 ||| NN
and  ||| S:2107 E:2111 ||| CC
treatment  ||| S:2111 E:2121 ||| NN
interval  ||| S:2121 E:2130 ||| VBZ
used  ||| S:2130 E:2135 ||| VBN
in  ||| S:2135 E:2138 ||| IN
the  ||| S:2138 E:2142 ||| DT
correction  ||| S:2142 E:2153 ||| NN
of  ||| S:2153 E:2156 ||| IN
glabellar  ||| S:2156 E:2166 ||| JJ
lines ||| S:2166 E:2171 ||| NNS
,  ||| S:2171 E:2173 ||| ,
induction  ||| S:2173 E:2183 ||| VBG
of  ||| S:2183 E:2186 ||| IN
neutralizing  ||| S:2186 E:2199 ||| JJ
antibodies  ||| S:2199 E:2210 ||| NNS
to  ||| S:2210 E:2213 ||| TO
BoNTA-ABO  ||| S:2213 E:2223 ||| NNP
was  ||| S:2223 E:2227 ||| VBD
not  ||| S:2227 E:2231 ||| RB
observed ||| S:2231 E:2239 ||| VBD
.  ||| S:2239 E:2241 ||| .
None  ||| S:2241 E:2246 ||| NN
of  ||| S:2246 E:2249 ||| IN
the  ||| S:2249 E:2253 ||| DT
five  ||| S:2253 E:2258 ||| CD
samples  ||| S:2258 E:2266 ||| NNS
that  ||| S:2266 E:2271 ||| WDT
initially  ||| S:2271 E:2281 ||| RB
gave  ||| S:2281 E:2286 ||| VBD
positive  ||| S:2286 E:2295 ||| JJ
results  ||| S:2295 E:2303 ||| NNS
in  ||| S:2303 E:2306 ||| IN
a  ||| S:2306 E:2308 ||| DT
RIPA-C  ||| S:2308 E:2315 ||| JJ
assay  ||| S:2315 E:2321 ||| NN
were  ||| S:2321 E:2326 ||| VBD
positive  ||| S:2326 E:2335 ||| JJ
when  ||| S:2335 E:2340 ||| WRB
further  ||| S:2340 E:2348 ||| RB
evaluated  ||| S:2348 E:2358 ||| VBN
using  ||| S:2358 E:2364 ||| VBG
the  ||| S:2364 E:2368 ||| DT
MPA ||| S:2368 E:2371 ||| NNP
.  ||| S:2371 E:2373 ||| .
Clinically ||| S:2373 E:2383 ||| NNP
,  ||| S:2383 E:2385 ||| ,
RIPA-C-positive  ||| S:2385 E:2401 ||| JJ
status  ||| S:2401 E:2408 ||| NN
did  ||| S:2408 E:2412 ||| VBD
not  ||| S:2412 E:2416 ||| RB
correlate  ||| S:2416 E:2426 ||| VBN
with  ||| S:2426 E:2431 ||| IN
any  ||| S:2431 E:2435 ||| DT
reduction  ||| S:2435 E:2445 ||| NN
in  ||| S:2445 E:2448 ||| IN
efficacy  ||| S:2448 E:2457 ||| NN
or  ||| S:2457 E:2460 ||| CC
an  ||| S:2460 E:2463 ||| DT
altered  ||| S:2463 E:2471 ||| JJ
safety  ||| S:2471 E:2478 ||| NN
profile ||| S:2478 E:2485 ||| NN
,  ||| S:2485 E:2487 ||| ,
although  ||| S:2487 E:2496 ||| IN
the  ||| S:2496 E:2500 ||| DT
small  ||| S:2500 E:2506 ||| JJ
numbers  ||| S:2506 E:2514 ||| NNS
prevent  ||| S:2514 E:2522 ||| VBP
definitive  ||| S:2522 E:2533 ||| JJ
conclusions ||| S:2533 E:2544 ||| NNS
.  ||| S:2544 E:2546 ||| .
These  ||| S:2546 E:2552 ||| DT
data  ||| S:2552 E:2557 ||| NNS
suggest  ||| S:2557 E:2565 ||| VBP
that  ||| S:2565 E:2570 ||| IN
the  ||| S:2570 E:2574 ||| DT
five  ||| S:2574 E:2579 ||| CD
RIPA-C-positive  ||| S:2579 E:2595 ||| JJ
samples  ||| S:2595 E:2603 ||| NNS
represented  ||| S:2603 E:2615 ||| VBD
false  ||| S:2615 E:2621 ||| JJ
positives ||| S:2621 E:2630 ||| NN
.  ||| S:2630 E:2632 ||| .
